Education
About Us
Working with TipRanks
Follow Us
Daito Pharmaceutical Co., Ltd. (JP:4577)
:4577
RESEARCH TOOLSreports
Total Valuation
Daito Pharmaceutical Co., Ltd. has a market cap or net worth of ¥36.83B. The enterprise value is ¥39.50B.
Market Cap¥36.83B
Enterprise Value¥39.50B
Share Statistics
Daito Pharmaceutical Co., Ltd. has 30,096,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding30,096,880
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Daito Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 2.43%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)2.43%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee47.33M
Profits Per Employee1.78M
Employee Count1,070
Asset Turnover0.65
Inventory Turnover2.28
Valuation Ratios
The current PE Ratio of Daito Pharmaceutical Co., Ltd. is 19.5. Daito Pharmaceutical Co., Ltd.’s PEG ratio is ―.
PE Ratio19.5
PS Ratio―
PB Ratio―
Price to Fair Value0.58
Price to FCF―
Price to Operating Cash Flow20.39
PEG Ratio―
Income Statement
In the last 12 months, Daito Pharmaceutical Co., Ltd. had revenue of 50.64B and earned 1.91B in profits. Earnings per share was 62.72.
Revenue50.64B
Gross Profit8.64B
Operating Income2.62B
Pretax Income2.96B
Net Income1.91B
EBITDA7.41B
Earnings Per Share (EPS)62.72
Cash Flow
In the last 12 months, operating cash flow was 1.84B and capital expenditures -4.89B, giving a free cash flow of -3.05B billion.
Operating Cash Flow1.84B
Free Cash Flow-3.05B
Free Cash Flow per Share-101.27
Dividends & Yields
Daito Pharmaceutical Co., Ltd. pays an annual dividend of ¥20, resulting in a dividend yield of 4.36%
Dividend Per Share¥20
Dividend Yield4.36%
Payout Ratio83.68%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change11.23%
50-Day Moving Average1.21K
200-Day Moving Average1.07K
Relative Strength Index (RSI)52.00
Average Volume (3m)48.65K
Important Dates
Daito Pharmaceutical Co., Ltd. upcoming earnings date is Oct 9, 2025, TBA (Confirmed).
Last Earnings DateJul 11, 2025
Next Earnings DateOct 9, 2025
Ex-Dividend DateNov 27, 2025
Financial Position
Daito Pharmaceutical Co., Ltd. as a current ratio of 2.45, with Debt / Equity ratio of 22.85%
Current Ratio2.45
Quick Ratio1.37
Debt to Market Cap0.33
Net Debt to EBITDA1.31
Interest Coverage Ratio21.31
Taxes
In the past 12 months, Daito Pharmaceutical Co., Ltd. has paid 1.19B in taxes.
Income Tax1.19B
Effective Tax Rate0.40
Enterprise Valuation
Daito Pharmaceutical Co., Ltd. EV to EBITDA ratio is 5.35, with an EV/FCF ratio of -41.42.
EV to Sales0.78
EV to EBITDA5.35
EV to Free Cash Flow-41.42
EV to Operating Cash Flow6.72
Balance Sheet
Daito Pharmaceutical Co., Ltd. has ¥2.38B in cash and marketable securities with ¥10.49B in debt, giving a net cash position of -¥8.11B billion.
Cash & Marketable Securities¥2.38B
Total Debt¥10.49B
Net Cash-¥8.11B
Net Cash Per Share-¥269.60
Tangible Book Value Per Share¥1.71K
Margins
Gross margin is 17.06%, with operating margin of 5.18%, and net profit margin of 3.77%.
Gross Margin17.06%
Operating Margin5.18%
Pretax Margin5.84%
Net Profit Margin3.77%
EBITDA Margin14.64%
EBIT Margin6.08%
Analyst Forecast
The average price target for Daito Pharmaceutical Co., Ltd. is ¥1,370.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥1,370.00
Price Target Upside11.65% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast7.99%
EPS Growth Forecast-51.78%